Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sexual Dysfunctions, Psychological

ClinicalTrials.gov lists 1,131 trials for Sexual Dysfunctions, Psychological or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 51.

MeSH D020018 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 85 Phase 1/2 Phase 1/2 21 Phase 2 Phase 2 102 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 173 Phase 4 Phase 4 126 Not applicable Not applicable 386 Observational Observational 221 Phase 1 Phase 1 85 Phase 1/2 Phase 1/2 21 Phase 2 Phase 2 102 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 173 Phase 4 Phase 4 126 Not applicable Not applicable 386 Observational Observational 221

Trials per phase (log scale)

135 of the 1,131 trials are tagged with Sexual Dysfunctions, Psychological itself; the rest are tagged with a narrower condition beneath it.

Get the Sexual Dysfunctions, Psychological report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sexual Dysfunctions, Psychological trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 77

1996: 1 trials (Observational 1) 2000: 3 trials (Not applicable 2, Phase 2 1) 2001: 1 trials (Phase 2 1) 2002: 16 trials (Observational 1, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 3) 2003: 37 trials (Observational 1, Phase 4 14, Phase 3 20, Phase 2 2) 2004: 28 trials (Observational 1, Phase 4 13, Phase 3 11, Phase 2/3 1, Phase 2 1, Phase 1 1) 2005: 40 trials (Observational 9, Not applicable 6, Phase 4 15, Phase 3 5, Phase 2 5) 2006: 31 trials (Observational 2, Not applicable 3, Phase 4 5, Phase 3 11, Phase 2 7, Phase 1/2 1, Phase 1 2) 2007: 33 trials (Observational 9, Not applicable 4, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 3, Phase 1 6) 2008: 31 trials (Observational 3, Not applicable 4, Phase 4 4, Phase 3 9, Phase 2 2, Phase 1/2 1, Phase 1 8) 2009: 30 trials (Observational 3, Not applicable 1, Phase 4 8, Phase 3 13, Phase 2 4, Phase 1 1) 2010: 55 trials (Observational 8, Not applicable 6, Phase 4 5, Phase 3 14, Phase 2 6, Phase 1/2 1, Phase 1 15) 2011: 35 trials (Observational 6, Not applicable 4, Phase 4 4, Phase 3 11, Phase 2 5, Phase 1/2 1, Phase 1 4) 2012: 24 trials (Observational 5, Not applicable 10, Phase 4 6, Phase 3 2, Phase 2 1) 2013: 41 trials (Observational 10, Not applicable 11, Phase 4 4, Phase 3 4, Phase 2 6, Phase 1/2 1, Phase 1 5) 2014: 29 trials (Observational 3, Not applicable 12, Phase 4 4, Phase 3 5, Phase 2 1, Phase 1/2 1, Phase 1 3) 2015: 46 trials (Observational 9, Not applicable 13, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 11, Phase 1/2 3, Phase 1 7) 2016: 38 trials (Observational 8, Not applicable 15, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2017: 52 trials (Observational 12, Not applicable 23, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 4) 2018: 54 trials (Observational 9, Not applicable 30, Phase 4 2, Phase 3 4, Phase 2 6, Phase 1 3) 2019: 52 trials (Observational 17, Not applicable 21, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 1) 2020: 48 trials (Observational 14, Not applicable 16, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2021: 63 trials (Observational 17, Not applicable 31, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2022: 73 trials (Observational 20, Not applicable 30, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 11) 2023: 50 trials (Observational 4, Not applicable 32, Phase 4 3, Phase 3 4, Phase 2/3 2, Phase 2 1, Phase 1/2 2, Phase 1 2) 2024: 77 trials (Observational 15, Not applicable 47, Phase 4 2, Phase 3 5, Phase 2/3 3, Phase 2 4, Phase 1/2 1) 2025: 69 trials (Observational 15, Not applicable 34, Phase 4 5, Phase 3 5, Phase 2/3 2, Phase 2 3, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 67
2025 69
2024 77
2023 50
2022 73
2021 63
2020 48
2019 52
2018 54
2017 52

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 82 trials starting in 2026 and about 71 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 94 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 618 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sexual Dysfunctions, Psychological trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 85
Phase 1/2 21
Phase 2 102
Phase 2/3 17
Phase 3 173
Phase 4 126
Not applicable 386
Observational 221

How many Sexual Dysfunctions, Psychological trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 60
Recruiting 115
Enrolling by invitation 12
Active, not recruiting 29
Completed 639

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sexual Dysfunctions, Psychological trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bayer 51
Eli Lilly and Company 28
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 28
VIVUS LLC 16
Warner Chilcott 14

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Sexual Dysfunctions, Psychological? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
SILDENAFIL 71
AVANAFIL 16
Dapoxetine 16
Estradiol 14
Flibanserin 12

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tadalafil Pill 70
Vardenafil ODT (STAXYN, BAY38-9456) 53
Testosteron 14
[PRP] platelet rich plasma 13
type A botulinum toxin 9

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sexual Dysfunctions, Psychological trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Glucose, high (hyperglycemia) 32 1
metrorrhagia 27 1
abdominal pain 21 1
Creatinine 16 1
ALT, SGPT 12 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Sexual Dysfunctions, Psychological? (332)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Sexual Health in Hematopoietic Stem Cell Transplantation Survivors. Journal of the National Comprehensive Cancer Network : JNCCN 2025 Yes
Psychological and interpersonal dimensions of sexual function and dysfunction: recommendations from the fifth international consultation on sexual medicine (ICSM 2024). Sexual medicine reviews 2025 Yes
Evaluating a Digital Health Tool Designed to Improve Low Sexual Desire in Women: Mixed-Methods Implementation Science Study. Journal of medical Internet research 2025 Yes
Cognitive behavioural therapy for sexual concerns during menopause: evaluation of a four session protocol. The journal of sexual medicine 2025 Yes
Psychological and sexual impact of human papillomavirus screening in women in Cameroon: a prospective cohort study. BMC women's health 2025 Yes

Showing 5 of 332 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages